gerilimzumab
mAbexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02795299)
Timeline
Indications
Mechanism of action
- Interleukin-6INHIBITOR
IL6 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gerilimzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06799416 | Phase 1 | Jan 14, 2025 | argenx |
| NCT04179513 | Phase 1 | Aug 15, 2019 | Genor BioPharma Co., Ltd., Peking University |
| NCT04178070 | Phase 1 | Nov 6, 2017 | Genor BioPharma Co., Ltd., Peking University |
| NCT02795299 | Phase 2 | Nov 1, 2016 | Bird Rock Bio, Inc., Pharmagenix, Techtrials Pesquisa e Tecnologia Ltda |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genor BioPharma Co., Ltd. | For profit | 2 | 2 | 1 | 2017 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| argenx | For profit | 1 | 1 | 1 | 2025 |
| Bird Rock Bio, Inc. | For profit | 1 | 1 | 1 | 2016 |
| Pharmagenix | For profit | 1 | 0 | 1 | 2016 |
| Techtrials Pesquisa e Tecnologia Ltda | For profit | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1